ReviewAnnual review of pathology2008
Notch signaling in leukemia.
Review in Annual review of pathology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 163 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
163 citing papers in PubMed, 265 citations in OpenAlex.
- A Phase Ib/II Randomized Study of RO4929097, a Gamma-Secretase or Notch Inhibitor with or without Vismodegib, a Hedgehog Inhibitor, in Advanced Sarcoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Trial
- Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis).Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2017Trial
- Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling.Pediatric blood & cancer · 2012Trial
- A phase II study of RO4929097 in metastatic colorectal cancer.European journal of cancer (Oxford, England : 1990) · 2012Trial
- Trial
- Notch1 O-GlcNAcylation drives tumor stemness and mechanoadaptation to a stiff microenvironment and promotes chordoma recurrence.The Journal of clinical investigation · 2026Article
- MicroRNA-181a in acute lymphoblastic leukemia: expression pattern, target genes and its potential as a biomarker.Biochemistry and biophysics reports · 2026Review
- An era of immunological discoveries heralded by molecular biology.Trends in immunology · 2025Article
- The heterogeneity of NOTCH1 to tumor immune infiltration in pan-cancer.Scientific reports · 2024Article
- Inhibiting AGTR1 reduces AML burden and protects the heart from cardiotoxicity in mouse models.Science translational medicine · 2024Article
- Notch signaling regulates UNC5B to suppress endothelial proliferation, migration, junction activity, and retinal plexus branching.Scientific reports · 2024Article
- Non-canonical non-genomic morphogen signaling in anucleate platelets: a critical determinant of prothrombotic function in circulation.Cell communication and signaling : CCS · 2024Review
- CanCHD Study of Hematopoietic Cancers in Children With and Without Genetic Syndromes.Journal of the American Heart Association · 2024Article
- Proto-oncogene mutations in middle ear cholesteatoma contribute to its pathogenesis.BMC medical genomics · 2023Article
- Ferroptosis and EMT: key targets for combating cancer progression and therapy resistance.Cellular and molecular life sciences : CMLS · 2023Review
- Review
- Article
- Article
- Functional Comparison between Endogenous and Synthetic Notch Systems.ACS synthetic biology · 2022Article
- Article
103 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
Recent discoveries indicate that gain-of-function mutations in the Notch1 receptor are very common in human T cell acute lymphoblastic leukemia/lymphoma. This review discusses what these mutations have taught us about normal and pathophysiologic Notch1 signaling, and how these insights may lead to new targeted therapies for patients with this aggressive form of cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.